When the number is dramatic, but the biology is benign.
This post walks through a real inpatient hematology consult, step by step, to show how experienced consultants organize their thinking over time when faced with a striking laboratory abnormality and an intuitive but often misleading treatment reflex.
The phases are named explicitly to make visible what is usually implicit in practice.
The goal is not to review causes of thrombocytosis or to provide a dosing guide for antiplatelet therapy. The goal is to model judgment as it unfolds when the number is dramatic, the anxiety is real, and the decision to intervene may be driven more by discomfort than by biology.
Opening scenario
You are asked to consult on a hospitalized patient.
A brief note: postoperative thrombocytosis consults rarely arrive as isolated lab values. The surgical context and timeline are part of the signal.
A 66-year-old woman is postoperative day 7 after major abdominal surgery. Her recovery has been uncomplicated. She is ambulating, afebrile, and hemodynamically stable.
Morning labs reveal a platelet count of 1.1 million/µL.
The primary team asks whether she should be treated with aspirin.
No additional details are provided.
Companion resources (in development)
Cause-based frameworks and quick-reference tools for common inpatient hematology problems are being developed as part of TBP’s consult reasoning series. They are meant to be used after initial orientation and framing, not in place of them.
How to use this post when you get paged
This is not a diagnostic guide, and it is not meant to be read linearly at the bedside.
Instead, use it as a cognitive checklist at three moments:
- When the page comes in, use Phase 1 to orient to danger, urgency, and asymmetric risk before naming diagnoses.
- When you make your first recommendation, use Phase 2 and 3 to decide what stance you’re taking and how to communicate it clearly under uncertainty.
- When new information arrives, use Phase 4 to recalibrate without rewriting history.
The goal is not to tell you what to think, but to help you recognize what kind of thinking the situation demands.
Different consults demand different kinds of thinking
Some hinge on thresholds, where the central question is whether inaction has become more dangerous than action. Others require balancing harms, where no option is safe and the work lies in choosing which risk to accept. Still others require proportionality, where the diagnosis is known and the challenge is matching the mechanism of an intervention to how the disease is behaving over time.
The disease examples that follow are not exhaustive. They are illustrations meant to help you recognize these patterns when you are in the middle of one.
Phase 1: Initial Orientation
(Often begins at the time of the page)
Phase 1 involves rapid, provisional thinking under time pressure, aimed at defining danger and scope rather than committing to treatment.
In this consult, the first task is not to decide whether to lower the platelet count.
It is to decide whether the platelet count represents a problem that needs treatment at all.
Key orienting questions
(not ordered by importance)
Is the patient clinically unstable or showing signs of thrombosis or bleeding?
Symptoms matter more than the number. Headache, erythromelalgia, digital ischemia, bleeding, or neurologic changes would immediately shift concern.
What is the surgical context and timeline?
Postoperative thrombocytosis typically peaks one to two weeks after surgery. Timing helps distinguish reactive physiology from autonomous disease.
What else is happening biologically?
Inflammation, tissue injury, iron deficiency, infection, or recent bleeding can all drive platelet production.
Is there a prior platelet history?
A previously normal platelet count argues strongly against an underlying myeloproliferative disorder presenting de novo.
What antithrombotic measures are already in place?
Most postoperative patients are already receiving venous thromboembolism prophylaxis. Aspirin would be additive, not neutral.
Where is the patient right now?
ICU versus floor matters less here than clinical stability, but it still frames urgency and tolerance for watchful waiting.
At this stage, you are not deciding whether to start aspirin.
You are deciding whether this platelet count represents a dangerous state or a reactive signal.
By the end of Phase 1, the consultant should be able to say:
- I understand whether the patient is symptomatic
- I understand the postoperative timeline and context
- I know whether this is likely reactive or autonomous
- I know whether immediate harm is plausible
Phase 1 does not interpret mechanism or prescribe therapy.
It determines tempo and risk tolerance.
Phase 2: Diagnostic Framing
(Choosing a direction of reasoning)
Phase 2 begins once the consultant accepts that the platelet count is real and striking.
What changes here is not the data.
It is the frame.
At this point, the central move is a reframing one.
This looks dangerous because we are importing the wrong mental model.
The platelet count is real.
The risk we are projecting onto it is not.
Postoperative thrombocytosis is a reactive phenomenon. It reflects cytokine-driven marrow stimulation in response to tissue injury, inflammation, and recovery. It is not the same biological process as essential thrombocythemia, and it does not carry the same intrinsic thrombotic behavior.
When the wrong model is applied, magnitude is mistaken for mechanism. A number that feels extreme is assumed to carry extreme risk, even when the underlying physiology does not support that inference.
This is where many teams get stuck. The lab value demands action, but the biology does not.
The consultant’s task in Phase 2 is not to decide how aggressively to treat the platelet count. It is to decide whether the platelet count represents a disease state at all.
Pre-test probabilities, not premature closure — adapted
In many consults, Phase 2 is about ranking diagnoses by likelihood.
Here, the relevant question is simpler.
In a clinically stable postoperative patient with no prior thrombocytosis, the pre-test probability that a platelet count of one million represents a primary myeloproliferative disorder is very low.
Premature closure here does not mean missing a rare diagnosis. It means acting on a presumed risk that does not exist.
What informs framing in this consult
Context
Reactive thrombocytosis is common after major surgery. Its presence alone is not a signal of danger.
Symptoms
Thrombotic or vasomotor symptoms would change the frame. Their absence supports restraint.
Mechanism
Reactive thrombocytosis reflects increased platelet production, not abnormal platelet function.
Competing risks
Aspirin is not benign in the postoperative period. Bleeding risk is real, especially after abdominal surgery. In a patient already receiving VTE prophylaxis, aspirin adds risk without necessarily adding meaningful protection.
Trajectory
Reactive platelet counts peak and fall. Stability or spontaneous decline reinforces the reactive model.
A nuance worth naming: there are postoperative contexts where baseline thrombosis risk is higher (for example, splenectomy, active malignancy, prolonged immobility). In those situations, the decision is still not “treat the platelet count,” but “optimize thromboprophylaxis for the patient’s global risk,” and practice variation is real.
The role of high-impact discriminators
(In acute chest syndrome, these are often trends, not single tests)
Some information carries disproportionate weight once available.
Evidence of arterial thrombosis, unusual bleeding, or a history of sustained thrombocytosis would escalate concern. Their absence strongly favors observation.
Molecular testing, bone marrow biopsy, or cytoreductive therapy are not discriminators in this setting. They are distractions.
The output of Phase 2
The output is not a prescription.
It is a stance.
For example:
“This is reactive postoperative thrombocytosis. The number is impressive, but the biology does not support added antiplatelet therapy. We recommend observation.”
Or, less commonly:
“The platelet count may be reactive, but the patient has symptoms concerning for platelet-mediated microvascular disturbance. Aspirin may be reasonable while we evaluate further.”
That stance now needs to be communicated.
Aspirin is a treatment for the clonal model, not the reactive one.
In essential thrombocythemia and related myeloproliferative disorders, aspirin is used to reduce platelet-mediated microvascular symptoms and arterial risk because platelet function is abnormal and risk is disease-intrinsic.
In reactive postoperative thrombocytosis, the platelet count can be extreme without behaving like that disease. Treating the number with aspirin imports the clonal playbook into a reactive physiology.
What Phase 2 does—and does not—do
Phase 2 does:
- distinguish reactive physiology from autonomous platelet disease
- identify whether symptoms or true harm signals are present
- weigh competing risks of intervention in the postoperative setting
- clarify what would make you change your stance
Phase 2 does not:
- treat magnitude as mechanism
- escalate workup simply because the number is high
- prescribe aspirin to relieve team discomfort
Phase 3: Communicating the Consult
(Expressing judgment clearly)
In this consult, communication is the intervention.
Internal communication
Within the consult team, this is where anxiety is named explicitly.
Are we reacting to the number, or to evidence of harm? Are we trying to eliminate discomfort, or risk?
Clarifying that distinction prevents reflexive treatment.
External communication
To the primary team, effective communication separates acknowledgment from action.
This includes:
- affirming that the platelet count is real and striking
- explaining why reactive thrombocytosis behaves differently
- naming the risks of aspirin in the postoperative setting
- stating clearly that observation is an active decision
Saying “we don’t recommend aspirin” without explaining why invites distrust. Saying “this is normal” without acknowledging discomfort invites dismissal.
Phase 4: Recalibration Over Time
(Revising judgment as new information arrives)
Phase 4 begins as time adds information.
In postoperative thrombocytosis, recalibration is driven less by new tests than by clinical stability and trajectory.
Counts may plateau or fall. The patient may remain asymptomatic. The surgical recovery may proceed uneventfully.
These changes do not simply add reassurance.
They confirm the model.
Recalibration is about timing, not better reasoning
Earlier phases rely on what can reasonably be inferred in real time. Phase 4 acknowledges that dramatic numbers often provoke premature action, and that time is the antidote.
What matters is not whether the initial stance was provisional, it almost always was, but whether it is revisited honestly as the picture evolves.
Recalibration in practice
When I first saw this patient, the platelet count was over one million. The team was understandably concerned.
At that point, the absence of symptoms, the postoperative timing, and the lack of prior thrombocytosis supported a reactive process. We recommended observation without aspirin.
Over the next several days, the patient remained clinically well. The platelet count plateaued and then began to fall.
Nothing dramatic happened, and that was the point.
Externally, we closed the loop by naming what the trajectory meant: the falling count was not just “good news,” it was confirmation that no additional hematologic workup or platelet-directed therapy was needed.
In other cases, recalibration moves in the opposite direction. New symptoms emerge. The context changes. The model no longer fits. Intervention becomes appropriate.
What matters is not the direction of recalibration, but that it is explicit.
Communication revisited
As the picture evolves, internal discussion recalibrates confidence, and external communication reinforces why restraint remains appropriate, or why the stance has changed.
Changing one’s mind here is not a failure.
It is the work.
What Phase 4 demands of the consultant
Phase 4 asks the consultant to tolerate visible inaction.
Resisting aspirin does not mean ignoring risk. It means aligning action with mechanism rather than magnitude.
Good consult practice requires the ability to explain why doing less is sometimes the safer choice, and to revisit that decision without defensiveness if the picture changes.
Credibility is not built by reacting to numbers.
It is built by staying aligned with biology over time.
Closing reflection
Postoperative thrombocytosis feels dangerous because the number is extreme.
But danger does not live in the number alone.
Urgency is defined before treatment.
Direction is chosen before certainty.
Judgment is communicated before resolution.
And conclusions are revised as reality evolves.
Good consulting in postoperative thrombocytosis is not about suppressing platelet counts.
It is about recognizing when a dramatic signal reflects recovery rather than disease, and having the discipline not to treat discomfort as pathology.